Results 81 to 90 of about 749,373 (347)

Strength through diversity: how cancers thrive when clones cooperate

open access: yesMolecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken   +3 more
wiley   +1 more source

Laparoscopic pancreaticoduodenectomy: are the best times coming?

open access: yesWorld Journal of Surgical Oncology, 2019
Background The introduction of laparoscopic technology has greatly promoted the development of surgery, and the trend of minimally invasive surgery is becoming more and more obvious.
Mengqi Liu   +9 more
doaj   +1 more source

Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors

open access: yesBMC Surgery, 2022
Background Although some factors that predict the prognosis in pancreatic neuroendocrine tumor (pNET) have been confirmed, the predictive value of lymph node metastasis (LNM) in the prognosis of pNETs remains conflicting and it is not clear whether ...
Zheng Zhang   +14 more
doaj   +1 more source

A case of pancreatic cancer with concomitant median arcuate ligament syndrome treated successfully using an allograft arterial transposition [PDF]

open access: yes, 2015
An association of pancreatic cancer and median arcuate ligament syndrome (MALS) is a rare and challenging situation in terms of treatment. A 60-year-old man diagnosed with pancreatic cancer underwent laparotomy. A pancreaticoduodenectomy was planned, but
Bektas, Hüseyin   +4 more
core   +1 more source

A unified model for Duchenne muscular dystrophy gene involvement in cancer: context‐dependent tumour suppression and oncogenicity

open access: yesFEBS Open Bio, EarlyView.
We propose a context‐dependent model where the Duchenne muscular dystrophy (DMD) gene acts as a tumour suppressor in aggressive tumours and as an oncogene in less aggressive ones. We propose this model as a unified framework to explain the opposing survival associations with DMD expression and to guide experimental exploration of the dual role of DMD ...
Lee Machado   +4 more
wiley   +1 more source

Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide

open access: yesBMC Cancer
Background Ki67 index changes during the treatment of metastatic pancreatic neuroendocrine tumor (PanNET) treatment. The study aimed to detect alterations of grade based on Ki67 index and immune microenvironment in PanNET responding to capecitabine ...
Heli Gao   +14 more
doaj   +1 more source

AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN

open access: yesWorld Journal of Surgical Oncology, 2019
Background Both the 7th and 8th editions of the American Joint Committee on Cancer (AJCC) staging systems have been introduced for pancreatic adenocarcinoma.
Zhiyao Fan   +9 more
doaj   +1 more source

A case of pancreatic head cancer with Trousseau’s syndrome treated with radical resection and anticoagulant therapy

open access: yesSurgical Case Reports, 2023
Background The primary disease of Trousseau’s syndrome is often highly advanced cancer, and treatment of the primary disease after cerebral infarction is often difficult. We herein report a case of pancreatic head cancer with Trousseau’s syndrome treated
Takumi Kitahama   +6 more
doaj   +1 more source

YOD1 serves as a potential prognostic biomarker for pancreatic cancer [PDF]

open access: gold, 2022
Zhishuo Zhang   +8 more
openalex   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

open access: yes, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada   +119 more
core   +1 more source

Home - About - Disclaimer - Privacy